Company intelligence / Profile preview

Dolce Cann Global

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Dolce Cann Global is an Australian-based biotechnology company focused on the research, development, and cultivation of medicinal cannabis. The company specializes in identifying and stabilizing unique cannabis genetics to produce high-quality, pharmaceutical-grade cannabinoids for therapeutic use. Their business model integrates the entire value chain from genomic research and breeding to the manufacturing of standardized medicinal products. Dolce Cann Global aims to address unmet medical needs in areas such as chronic pain, epilepsy, and inflammatory disorders through evidence-based cannabinoid therapies.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: Small moleculePhytocannabinoids
Industry: Biotech

Beyond the preview

Go deeper on Dolce Cann Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dolce Cann Global.

Explore the full profile